Healthcare / Drug Manufacturers - Specialty & GenericBSE
$2260.65
+41.35 (+1.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $131.4M · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$23.5B
P/E
34.9x
↑EV/EBITDA
20.6x
↑ROE
20.3%
↑Gross Margin
48.6%
↑Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+26.1%
FCF CAGR
—
FCF margin
-6.4%
FCF / Net income
-0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.03B · net income $673.5M · FCF $-323.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.03B | $5.03B | $3.70B | $3.07B | $2.51B |
| Net Income | $673.5M | $673.5M | $398.5M | $238.0M | $193.7M |
| EBITDA | $1.20B | $1.20B | $823.1M | $610.4M | $465.5M |
| EPS | — | — | 38.36 | 22.93 | 18.67 |
| Gross Margin | 48.6% | 48.6% | 50.7% | 46.8% | 52.4% |
| Operating Margin | 19.6% | 19.6% | 16.8% | 15.2% | 18.2% |
| Net Margin | 13.4% | 13.4% | 10.8% | 7.7% | 7.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.43 | 0.44 | 0.45 |
| Current Ratio | 1.80 | 1.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-323.5M | $-323.5M | $277.2M | $131.4M | $-62.9M |
| Returns | |||||
| ROE | 20.3% | 20.3% | 15.1% | 10.6% | 9.7% |
| Valuation | |||||
| P/E | 34.89 | 34.89 | 21.60 | 20.87 | 17.02 |
| EV/EBITDA | 20.58 | 20.58 | 11.68 | 9.70 | 8.96 |
| P/B | 7.07 | 7.07 | 3.26 | 2.21 | 1.64 |
| Growth & Yield | |||||
| Revenue Growth | 35.9% | 35.9% | 20.6% | 22.3% | — |
| EPS Growth | — | — | 67.3% | 22.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+137.9%
Start / end P/E
n/dx → n/dx
EPS bridge
38.36 → n/d
Residual
+137.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.